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Objective: The aim of this study was to explore perceptions of patients with rheumatic diseases 
treated with subcutaneous (SC) biological drugs on the impact on daily life and satisfaction 
with current therapy, including preferred attributes.
Methods: A survey was developed ad hoc by four rheumatologists and three patients, including 
Likert questions on the impact of disease and treatment on daily life and preferred attributes of 
treatment. Rheumatologists from 50 participating centers were instructed to handout the survey 
to 20 consecutive patients with rheumatoid arthritis (RA), axial spondyloarthritis (ax-SpA), or 
psoriatic arthritis (PsA) receiving SC biological drugs. Patients responded to the survey at home 
and sent it to a central facility by prepaid mail.
Results: A total of 592 patients returned the survey (response rate: 59.2%), 51.4% of whom 
had RA, 23.8% had ax-SpA, and 19.6% had PsA. Patients reported moderate-to-severe impact 
of their disease on their quality of life (QoL) (51.9%), work/daily activities (49.2%), emotional 
well-being (41.0%), personal relationships (26.0%), and close relatives’ life (32.3%); 30%–50% 
patients reported seldom/never being inquired about these aspects by their rheumatologists. 
Treatment attributes ranked as most important were the normalization of QoL (43.6%) and the 
relief from symptoms (35.2%). The satisfaction with their current antirheumatic therapy was 
high (.80% were “satisfied” or “very satisfied”), despite moderate/severe impact of disease.
Conclusion: Patients with rheumatic diseases on SC biological therapy perceive a high disease 
impact on different aspects of daily life, despite being highly satisfied with their treatment; the 
perception is that physicians do not frequently address personal problems. Normalization of 
QoL is the most important attribute of therapies to patients.
Keywords: rheumatic diseases, quality of life, emotional well-being, biological drugs, patient’s 
satisfaction
Introduction
Rheumatic diseases are among the most common chronic diseases, being a major 
cause of disability in developed countries and consuming a large amount of health 
care and social resources.1,2 Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and 
axial spondyloarthritis (ax-SpA) have a chronic course, requiring lifelong manage-
ment and causing a negative impact on quality of life (QoL).3,4 QoL in rheumatic 
diseases is determined not only by clinical symptoms but also by physical and social 
functioning.5,6 In turn, impaired health-related QoL and physical function are directly 
related to the socioeconomic impact of the disease.7 In addition, rheumatic diseases 
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impact highly on emotional well-being, fact frequently 
overseen by rheumatologists.8 For these reasons, assessing 
the QoL and its determinants as well as the impact of disease 
and treatment on patients’ daily life is important.
The availability of biological therapies has proven 
enormous benefits in attaining a better disease control and, 
consequently, improving the functional capacity and QoL 
of patients with RA, PsA, and ax-SpA.9–11 However, the 
efficacy of these drugs is still limited and the percentage 
of patients achieving a normal QoL is still insufficient.9–11 
Although validated instruments are available to measure 
different aspects of QoL, information directly obtained from 
patients through surveys can give complementary informa-
tion on aspects that validated questionnaires do not usually 
address. With the aim of exploring patients’ perceptions on 
the burden of rheumatic diseases in their daily life and their 
expectations and satisfaction with the antirheumatic therapy, 
we implemented a survey to patients with rheumatic diseases 
treated with subcutaneous (SC) biological drugs.
Methods
RHEU-LIFE was a survey launched in September and 
October 2015. Patients were eligible if they were adults 
with a diagnosis of one of the three target diseases, namely 
RA, ax-SpA, and PsA, and were being treated with SC 
biological drugs at the time of the survey and at least since 
the last medical appointment, and were able to understand 
and respond the survey in the opinion of the treating rheuma-
tologist. Patients being prescribed a first biological drug as 
of the survey date were not eligible. Rheumatologists from 
50 participating centers were instructed to handout a printed 
survey to the first 20 consecutive patients attending their out-
patient clinics who fulfilled the selection criteria, regardless 
of age, gender, disease severity, or duration of disease.
Patients received a closed envelope with the printed 
survey, and a cover letter explaining its purpose and clari-
fying the anonymous and voluntary nature of the survey. 
Patients were instructed to respond at home and to return the 
completed form directly to a central facility by prepaid mail. 
No reminders were sent to patients, and no clinical data were 
collected by physicians from patients’ clinical records.
The questions included in the survey were developed by 
four rheumatologists and reviewed and discussed in full by 
three patient representatives from the Spanish umbrella asso-
ciation of arthritis patients, Coordinadora Nacional de Artritis 
(ConArtritis), ensuring the appropriateness of the questions 
and the language used. The final survey contained 54 multiple-
choice items exploring the following aspects: perception on 
the impact of disease on daily life, sources of information 
on disease and treatments, expectations from medications, 
satisfaction with current treatment and with specific features 
of treatment, and some logistical aspects on dispensation of 
their SC medication and follow-up.
The impact of disease on daily life was explored through 
different aspects: QoL in general, emotional well-being, 
work or daily activities, personal relationships, and family 
life. For each of these aspects, patients selected one of the 
four closed options: “no impact”, “mild”, “moderate”, and 
“severe impact”. Patients were also requested to respond 
how frequently their treating physicians discussed the above-
mentioned topics with them (response categories: “always or 
nearly always”, “frequently”, “only sometimes”, and “never 
or seldom”). With regard to what patients expect from treat-
ments, patients were requested to rank the importance, from 1 
(the most important) to 5 (the less important), of the following 
attributes: control of symptoms, tolerability, speed of action, 
easiness of use, and normalization of QoL. For each attribute, 
patients were requested to rate the level of satisfaction with 
their current therapy (response categories: “very satisfied”, 
“satisfied”, “neutral [neither satisfied nor unsatisfied]”, 
“unsatisfied”, or “very unsatisfied”). The whole content of 
the survey is provided as Supplementary material.
ethical considerations
The survey and the working procedures were reviewed and 
approved by the Ethics Committee of the Gregorio Marañón 
University Hospital, Madrid, Spain, and by the Spanish 
association of patients with arthritis, ConArtritis. The survey 
included an instruction page for patients in which the anony-
mous and voluntary nature of the survey was described. Thus, 
return of completed questionnaires was considered implied 
consent to participate.
statistical considerations
Due to the exploratory nature of the study, no formal hypoth-
esis or prespecified sample size was set and no imputation 
was made for missing values. Quantitative variables are 
expressed as mean and standard deviation (SD), or median 
and interquartile range (IQR) if data were not distributed 
normally; qualitative variables are described as absolute and 
relative frequencies.
The influence of by age, gender, diagnosis, duration of 
the disease (.10 or ,10 years), and source of care (self-
care versus support from others) on perceived impact of 
disease was analyzed by chi-square and Fisher’s exact tests. 
Comparisons of several subgroups were made using the 
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nonparametric Kruskal–Wallis test. The association of vari-
ables to perceived impact was analyzed with multivariate 
logistic regression, and results presented as odd ratio with 
95% confidence intervals (CIs). In the models, the dependent 
variables were dichotomized responses of the items (“severe/
moderate” versus “mild/none”) and the explanatory variables 
included age (in quartiles), gender, diagnosis (RA, PsA, and 
ax-SpA), disease duration (above or below the median), 
and source of care (support from others versus self-care). 
Given the descriptive nature of the results, no multiplicity 
adjustments were made. A P-value of 0.05 was considered 
statistically significant. Statistical analysis was done using 
the SPSS program Version 18.0.0.
Results
response rate and sample description
The survey was handed to 1,000 patients and was returned by 
592 (response rate 59.2%). The mean age of the respondents 
was 41.7 years (SD 13.1), and 57.6% of them were females. 
The highest educational level achieved by the respondents 
was university or higher in 23.0%, technical studies in 
13.6%, and elementary school in 54.8%; 8.3% referred no 
formal studies. Regarding work-related variables, 42.5% 
were actively working, 13.0% were housekeepers, 20.3% 
were retired, 7.0% were unemployed, and 14.2% were on 
sick leave (2.7% temporal leave, 9.5% permanent leave 
due to their rheumatic disease, and 1.9% leave due to other 
reasons). The distribution of rheumatic diseases was 304 
RA (51.4%), 141 ax-SpA (23.8%), and 116 PsA (19.6%); 
thirty-one patients (5.2%) did not identify their disease. The 
median disease duration was 10 years (P
25–75
: 5–18). The SC 
biological drug was the first biological drug for 60.4% of the 
patients, the second for 26.1% of the patients, and the third 
or successive for 13.5% of the patients.
impact of the rheumatic disease in 
daily life
Table 1A shows the perceived impact of the rheumatic dis-
ease on different spheres of daily life. QoL and daily work 
or activity were the items on which patients described the 
highest perceived impact, with ~50% of patients reporting 
moderate-to-severe impact. The impact on the different 
spheres did not differ significantly by diagnosis. Females 
tended to perceive higher levels of impact than males in 
all spheres (P,0.05 for all the comparisons; Figure 1A). 
Similarly, patients with the duration of disease above the 
median ($10 years; Figure 1B) and older patients reported 
higher levels of perceived impact than their counterparts. 
Finally, those whom others cared for reported higher impact 
of disease on personal relationships and on close relatives’ 
lives than those who took care of themselves (Figure 1C).
The resulting models of factors associated with perceived 
impact are displayed in Table 1B. Female gender and dis-
ease duration were associated with “severely/moderately” 
perceived impact on all daily life spheres. Older age and 
diagnosis (PsA or SpA versus RA) were associated with 
worse perception in several spheres, and care by others was 
associated with impact on patients’ personal relationships 
and close relatives’ lives.
The vast majority of patients agreed that, during the 
medical interview, their rheumatologists inquire them always 
or frequently about their symptoms (95.8%) and about 
their QoL (75.7%). However, rheumatologists much rarely 
inquired about emotional well-being, work or daily activities, 
or personal relationships (Table 2).
satisfaction with their current therapy 
and treatment attributes preferred by 
patients
The attribute most frequently mentioned as the most impor-
tant for patients (more frequently ranked as 1) was that the 
medication helped normalizing QoL (43.6%), followed by 
the control of symptoms (35.2%); other attributes were men-
tioned less frequently (Figure 2). Gender and diagnosis did 
not show an association with the attribute raking. Also, there 
were no differences in the preferred attributes with regard to 
the number of biological drugs administered previously (first, 
second, and third or successive) (data not shown).
Overall, patients reported to be highly satisfied with 
their current antirheumatic therapy, with .80% being 
satisfied or very satisfied with each of the abovementioned 
attributes (Figure 3); and only ~5% reporting “unsatisfied” 
or “very unsatisfied”. Similar figures were seen for males 
and females. The percentage of patients satisfied was higher 
among those patients perceiving none or mild impact of 
disease than among those perceiving moderate-to-severe 
impact (Figure 4); however, the level of satisfaction with 
treatment was not low among patients with moderate-to-
severe impact of disease, with .70% reporting being satis-
fied or very satisfied (Figure 4). The percentage of patients 
satisfied or very satisfied was higher among those patients 
treated with the first SC biological drug than among those 
treated with the second, third, or successive drugs for the 
normalization of QoL (85.7, 76.8, and 72.0%, respectively, 
P=0.007), the control of symptoms (87.8, 84.2, and 78.4%, 
respectively, P=0.097), and speed of action (83.5, 74.2, 
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Table 1 Perceived impact of the rheumatic disease on daily life domains and associated variables
(A) Percentage of patients responding to “how much do you consider your rheumatic disease impacts your…?”
None Mild Moderate Severe
Quality of life (n=569) (%) 15.6 32.5 32.2 19.7
emotional well-being (n=571) (%) 19.3 39.8 26.6 14.4
Daily work or activities (n=565) (%) 16.3 34.5 28.0 21.2
Personal relationships (n=570) (%) 41.8 32.3 17.2 8.8
Family (close relatives) life (n=570) (%) 27.2 40.5 20.2 12.1
(B) Multivariable analysis of factors associated to perceived impact (“moderate/severe” versus “none/mild”) on different aspects of daily life
OR (95% CI) P-value
Quality of life
Age (per quartile increase) 1.30 (1.08–1.58) 0.006
Female gender (versus male) 1.62 (1.07–2.47) 0.024
PsA (versus rA) 1.76 (1.04–2.97) 0.034
Disease duration $10 years (versus ,10 years) 1.72 (1.14–2.59) 0.009
emotional well-being
Female gender (versus male) 1.74 (1.14–2.67) 0.024
PsA (versus rA) 1.66 (0.99–2.77) 0.055
Disease duration $10 years (versus ,10 years) 1.87 (1.24–2.87) 0.003
Daily work or activities
Age (per quartile increase) 1.29 (1.07–1.56) 0.009
Female gender (versus male) 1.91 (1.25–2.90) 0.003
Axial spA (versus rA) 1.61 (0.97–2.66) 0.066
Disease duration $10 years (versus ,10 years) 1.53 (1.02–2.31) 0.041
Personal relationships
Female gender (versus male) 1.90 (1.61–3.11) 0.003
Axial spA (versus rA) 1.74 (0.98–3.09) 0.060
PsA (versus rA) 1.73 (0.97–3.10) 0.065
Disease duration $10 years (versus ,10 years) 1.93 (1.19–3.12) 0.008
care from others (versus only self-care) 1.37 (1.08–1.74) 0.010
Family (close relatives) life
Age (per quartile increase) 1.20 (0.97–1.47) 0.092
Female gender (versus male) 2.01 (1.28–3.29) 0.003
Disease duration $10 years (versus ,10 years) 2.01 (1.27–3.12) 0.003
care from others (versus only self-care) 1.57 (1.25–1.98) ,0.001
Abbreviations: CI, confidence interval; OR, odds ratio; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, spondyloarthritis.
Figure 1 (Continued)
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Table 2 rheumatologists’ behavior as perceived by patients
Always/nearly 
always
Frequently Only 
sometimes
Never/seldom 
ever
inquires about my symptoms (n=539) (%) 77.2 18.6 3.3 0.9
inquires about how my disease affects my quality of life (n=526) (%) 50.0 25.7 16.2 8.2
inquires about how my disease affects my emotional well-being (n=519) (%) 37.4 24.3 17.5 20.8
inquires about how my disease affects my daily work or activities (n=520) (%) 43.7 24.8 17.7 13.8
inquires about how my disease affects my personal relationships (n=513) (%) 32.0 18.5 18.9 30.6
Note: Frequency with which rheumatologists inquire patients about different aspects of their lives during clinical visits.
Figure 1 Perceived impact of rheumatic disease, by gender (A), disease duration (B), and source of care (C).
Note: Bottom numbers in bars represent the percentage of patients reporting that their rheumatic disease has a moderate-to-severe impact on different aspects of daily life.









6HOIFDUH 6HOIFDUH 6HOIFDUH)URPRWKHUV )URPRWKHUV )URPRWKHUV 6HOIFDUH )URPRWKHUV 6HOIFDUH
&ORVHUHODWLYHVOLIH33HUVRQDOUHODWLRQVKLSV3 'DLO\ZRUNRUDFWLYLW\3 (PRWLRQDOOHYHO3 4XDOLW\RIOLIH3 
)URPRWKHUV
         











\HDUV \HDUV \HDUV\HDUV \HDUV \HDUV \HDUV \HDUV \HDUV
&ORVHUHODWLYHVOLIH33HUVRQDOUHODWLRQVKLSV3'DLO\ZRUNRUDFWLYLW\3(PRWLRQDOOHYHO34XDOLW\RIOLIH3
\HDUV
         


0RGHUDWHVHYHUH 0LOG 1RQH
%
&
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
14
4.
39
.2
01
 o
n 
19
-A
ug
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2017:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1248
gonzález et al
1RUPDOL]DWLRQRI4R/  
  

  



 
 

&RQWLQXRXVFRQWURORIV\PSWRPV
*RRGWROHUDELOLW\
6SHHGRIDFWLRQ
(DVHRIDGPLQLVWUDWLRQ
VWPRVWLPSRUWDQW QG UG WK WKOHDVWLPSRUWDQW

Figure 2 Patients’ attribution of importance to each treatment feature.
Note: results are expressed in percentage of respondents.
Abbreviation: Qol, quality of life.
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
&RQWLQXRXVFRQWURORIV\PSWRPV
*RRGWROHUDELOLW\
6SHHGRIDFWLRQ
(DVHRIDGPLQLVWUDWLRQ
9HU\VDWLVILHG 6DWLVILHG 1HXWUDO 8QVDWLVILHGYHU\XQVDWLVILHG
Figure 3 Patients’ satisfaction with current antirheumatic therapy.
Notes: Bars represent the percentage of patients into each category for the different features. Note that, for space reasons, the categories “unsatisfied” and “very 
unsatisfied” have been combined in the figure.
Abbreviation: Qol, quality of life.
and 73.2%, respectively, P=0.046) and similar for the toler-
ability and easiness of administration.
Discussion
Rheumatic and musculoskeletal diseases have been ranked 
as the second largest contributor to years lived with global 
disability,12 and rheumatic patients exhibit an impaired 
QoL compared to the general population and other chronic 
conditions.3,4 Our results contribute by adding patients’ per-
spective on how the disease impacts not only QoL but also 
emotional well-being, daily activities, their relationships, 
and the lives of their families, topics that, they report, are not 
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
14
4.
39
.2
01
 o
n 
19
-A
ug
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2017:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1249
impact of rheumatic diseases perceived by patients
frequently discussed with their treating physicians. From the 
multivariable models, we conclude that several differences 
exist with regard to age, gender, and the disease itself. Also, 
patients who need care from others acknowledge the impact 
of their disease in their close relatives. Patients prefer that 
drug therapies contribute to normalize QoL and control clini-
cal symptoms over tolerability or easiness of administration, 
which also arise as important therapy attributes, and express 
a high level of satisfaction with their current therapies.
Advanced age and female gender were associated 
with “moderate-to-severe” perceived impact on all daily 
life spheres. This was also found using the EuroQol 5D 
(EQ-5D) utility index in a recent study on patients with 
different rheumatic diseases from rheumatology outpatient 
clinics.13 Several studies have described a poorer response 
to pharmacological treatments of females than males with 
RA14,15 or SpA.16,17 Similarly, male gender has been found to 
be predictive for both response (BASDAI 50, ASAS 20, and 
ASAS 40) and treatment continuation in ax-SpA.16,17 While 
this can contribute to reduce QoL in females with regard to 
males, it has also been hypothesized that female patients score 
higher on subjective measures of disease activity specific 
to musculoskeletal performance, probably due to a general 
tendency toward reporting poorer scores in questionnaires.17 
Our finding that older patients and those with longer disease 
duration perceive higher impact of their rheumatic disease 
on daily life is congruent with previous reports.13 Also, our 
finding of a 14.2% of patients in sick leave is in line with 
the high proportion of patients describing moderate/severe 
impairment of QoL, emotional well-being, and work/daily 
activities, and it is not surprising in a sample of patients 
treated with biological drugs, with a median disease duration 
self-reported of 10 years.
In the RHEU-LIFE survey, patients acknowledge the 
impact of their disease on their personal relationships and 
on their close relatives’ lives; moreover, those who need 
support from others for their care rated worse in all items. 
Successful self-management interventions in patients with 
chronic illnesses require an integrated approach with impli-
cation not only of the patient and the health professional but 
also from the patient social environment: family, friends, and 
colleagues.18–20 Self-management support might be hampered 
by patients’ circumstances, such as depression, and also 
by poor physician communication or low family support.21 
In this regard, patients’ responses to this survey show that, 
during clinical visits, physicians focus their questions on 
clinical symptoms, but a significant percentage never, or only 
sometimes, ask their patients about how the disease affects 
their emotional well-being or their personal relationships, 
when these are aspects of daily life that patients have debili-
tated. The journey toward patient-centered health care models 
that integrate the perspectives and preferences of patients 
into the delivery of health care entails an effective patient–
physician partnership taking into account the individual 
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Figure 4 Patients’ satisfaction with current antirheumatic therapy, by the perception on impact on quality of life (moderate/severe versus none/mild).
Note: Bottom numbers in bars represent the percentage of patients reporting being satisfied or very satisfied with each treatment aspect.
Abbreviation: Qol, quality of life.
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patients values, needs, and life context (eg, home life, job, 
and family relationships) for decisions.22
Our survey also shows that the attributes of treatment 
most valued by patients – normalization of QoL and control 
of symptoms – are consistent with regarding QoL as a major 
target and patients’ preferences might be affected by this view. 
Notably, patients were satisfied with their medications even if 
they had serious impact of their diseases on their lives. This 
may indicate, on one hand, that medications are efficacious to 
relief symptoms and to improve QoL, but on the other hand, it 
could also indicate that patients get accustomed to living with 
certain degree of symptoms and QoL impairment. Thus, set-
ting expectations and objectives with patients is important and 
can contribute toward achieving better clinical outcomes.
Our study has several limitations. No clinical data were 
collected from clinical charts, so that “objective” activity could 
not be tested against perceived impact. Also, previous or cur-
rent specific treatments were not recorded so that we could 
not study the effect of these on responses. In addition, the 
survey was distributed to patients treated with SC biological 
drugs, what could be a selected group of severe patients, what 
precludes a generalization of our results to the more general 
population of patients with rheumatic diseases. The consecu-
tive sampling of patients could also lead to a selection of more 
severe patients. Nevertheless, this is the group of patients who 
can be more disrupted by the rheumatic disease and in which 
implementing specific actions can be more efficient. We also 
need taking into account that, as a survey, it did not follow a 
formal validation process as validated questionnaires use to 
follow. Although this is a limitation, the validity of the infor-
mation obtained lays on the fact that the content was generated 
with and reviewed by patients and the survey responds to what 
patients thought was important for them. Finally, as the survey 
was anonymous, the characteristics of the patients who did not 
respond to the survey are unknown, and because the survey 
was carried out in Spain, the results might not be generalizable 
to patients from different countries or cultures.
Conclusion
With all these limitations, perceptions from patients are 
always relevant for a patient-centered approach in health 
care. In this context, surveys like the present provide valuable 
additional information to that provided by clinical studies. 
Outpatients with rheumatic diseases under treatment with SC 
biological drugs describe a strong negative impact of their 
disease on different spheres of their daily life and in their 
relatives, but some of these topics are not addressed by the 
treating physician during clinical appointments. Consistent 
with the impact of patients’ perceive, they consider the 
improvement of QoL and the relief from symptoms as the 
most important attributes of therapies and show a high 
degree of satisfaction with the treatments they follow, which 
suggests that drugs are efficacious but also that patients get 
accustomed to tolerate certain disease burden. Addressing all 
these aspects from a comprehensive perspective is important 
for a patient-centered approach aiming to reduce the impact 
of the rheumatic diseases on patients’ daily life.
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